Merck

Views & Analysis

Inspiring a new generation of women in pharma

As part of a series of articles highlighting the role of women in the pharma industry, Richard Staines speaks to Louise Houson, MSD’s managing director for UK and Ireland

News

MSD and Pfizer top Dow for 2018

MSD and Pfizer were 2018’s top gainers on the Dow Jones Industrial Average for the calendar year, with both companies bucking the trend of an otherwise lacklustre year for the index.

News

Sanofi, Merck’s Vaxelis is first six-in-one vaccine in US

Sanofi and Merck & Co picked up late 2018 approval from the FDA during the holiday period, getting a green light for their six-in-one paediatric shot Vaxelis.

News

Merck takes a back seat on CAR-T, handing assets to Intrexon

Merck KGaA wants to get bigger in immuno-oncology, but from now on it won’t be taking a direct role in the drive to develop new CAR-T therapies.

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Merck bags adjuvant okay for Keytruda in melanoma

Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe.

News

Merck and Pfizer chalk up another fail for Bavencio

Merck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in ovarian cancer, denting their hopes of building momentum for the product.